NASDAQ:RYZB RayzeBio (RYZB) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free RYZB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$62.49▼$62.4950-Day Range$62.27▼$62.4952-Week Range$17.95▼$62.51VolumeN/AAverage Volume553,592 shsMarket Capitalization$3.74 billionP/E RatioN/ADividend YieldN/APrice Target$31.33 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get RayzeBio alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About RayzeBio Stock (NASDAQ:RYZB)RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.Read More Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide RYZB Stock News HeadlinesFebruary 29, 2024 | finance.yahoo.comAndreas Halvorsen's Firm Sells Out of RayzeBio IncFebruary 27, 2024 | finance.yahoo.comRYZB May 2024 55.000 putApril 29, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 27, 2024 | finance.yahoo.comRYZB Aug 2024 35.000 putFebruary 26, 2024 | businesswire.comBristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical PlatformFebruary 25, 2024 | ca.finance.yahoo.comBMY Mar 2024 54.000 putFebruary 24, 2024 | finance.yahoo.comBMY Apr 2024 43.000 putFebruary 24, 2024 | finance.yahoo.comBMY Mar 2024 48.000 callApril 29, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 24, 2024 | finance.yahoo.comBMY Mar 2024 47.000 putFebruary 24, 2024 | finance.yahoo.comBMY Mar 2024 43.000 putFebruary 23, 2024 | marketwatch.comBristol Myers Wraps RayzeBio Tender Offer with 86% of SharesFebruary 23, 2024 | businesswire.comBristol Myers Squibb Announces Expiration of RayzeBio Tender OfferFebruary 22, 2024 | benzinga.comRayzeBio Stock (NASDAQ:RYZB), Quotes and News SummaryFebruary 18, 2024 | finance.yahoo.comRYZB Feb 2024 65.000 callFebruary 13, 2024 | finance.yahoo.comBMY Feb 2024 37.000 putFebruary 12, 2024 | finance.yahoo.comBristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting PeriodDecember 31, 2023 | businesswire.comRAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZBDecember 31, 2023 | businesswire.comRAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZBDecember 28, 2023 | realmoney.thestreet.comRayzeBio just downgraded at JPMorgan, here's whyDecember 28, 2023 | msn.comRBC says Bristol Myers/RayzeBio deal validates Fusion 's approachDecember 28, 2023 | realmoney.thestreet.comRayzeBio downgraded to Hold from Buy at TruistDecember 26, 2023 | finance.yahoo.comBristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%December 26, 2023 | msn.comWhy RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionDecember 26, 2023 | finance.yahoo.comBristol Myers buying RayzeBio, FedEx buyback: Trending tickersDecember 26, 2023 | za.investing.comMidday movers: Intel, RayzeBio, and moreDecember 26, 2023 | benzinga.comHealth Care Company Bristol-Myers Squibb Announces Merger With RayzeBioSee More Headlines Receive RYZB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RayzeBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:RYZB CUSIPN/A CIK1825367 Webrayzebio.com Phone619-937-2754FaxN/AEmployees88Year FoundedN/APrice Target and Rating Average Stock Price Target$31.33 High Stock Price Target$35.00 Low Stock Price Target$29.00 Potential Upside/Downside-49.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio31.85 Quick Ratio31.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares59,920,000Free FloatN/AMarket Cap$3.74 billion OptionableOptionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Kenneth Song M.D. (Age 49)President, CEO & Director Comp: $646kMr. Arvind Kush (Age 41)Chief Financial Officer Comp: $714.76kDr. Susan Moran M.D. (Age 55)Chief Medical Officer Comp: $559.84kMr. Aron Marc Knickerbocker (Age 55)Co-Founder Mr. Jeff WoodleyGeneral CounselMr. Eric BischoffSenior Vice President of Development & OperationsDr. Gary G. Li Ph.D.Senior Vice President of Biology & Translational MedicineMs. Kimberly Ma M.S.Senior Vice President of Clinical OperationsDr. Nicholas D. Smith Ph.D.Senior Vice President of Chemistry InnovationMr. Abhi Bhat Ph.D.Senior VP of Chemistry & Head of DiscoveryMore ExecutivesKey CompetitorsBiohavenNYSE:BHVNIovance BiotherapeuticsNASDAQ:IOVAAmicus TherapeuticsNASDAQ:FOLDIntegerNYSE:ITGRCymaBay TherapeuticsNASDAQ:CBAYView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 371,777 shares on 3/5/2024Ownership: 5.848%Perceptive Advisors LLCSold 32,749 shares on 2/26/2024Ownership: 1.242%Blackstone Inc.Bought 8,090 shares on 2/15/2024Ownership: 0.180%Harvest Management LLCBought 50,000 shares on 2/14/2024Ownership: 0.083%PenderFund Capital Management Ltd.Bought 1,800 shares on 2/14/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions RYZB Stock Analysis - Frequently Asked Questions Should I buy or sell RayzeBio stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RayzeBio in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RYZB shares. View RYZB analyst ratings or view top-rated stocks. What is RayzeBio's stock price target for 2024? 5 Wall Street research analysts have issued twelve-month price targets for RayzeBio's shares. Their RYZB share price targets range from $29.00 to $35.00. On average, they predict the company's share price to reach $31.33 in the next twelve months. This suggests that the stock has a possible downside of 49.9%. View analysts price targets for RYZB or view top-rated stocks among Wall Street analysts. When did RayzeBio IPO? RayzeBio (RYZB) raised $311 million in an IPO on Friday, September 15th 2023. The company issued 17,277,600 shares at a price of $18.00 per share. When did RayzeBio's lock-up period expire? RayzeBio's lock-up period expired on Wednesday, March 13th. RayzeBio had issued 17,277,600 shares in its public offering on September 15th. The total size of the offering was $310,996,800 based on an initial share price of $18.00. Since the end of RayzeBio's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. This page (NASDAQ:RYZB) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RayzeBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
